Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scienture HoldingsSCNX -2.18%43 3-Year EPS without NRI Growth Rate is 28.50% as of Jun. 2026, which is 139% above its 10-year median of 11.90. GuruFocus rates SCNX with a GF Score™ of 43/100 and a GF Value™ of $0.51 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 503 Healthcare Providers & Services companies, Scienture Holdings ranks better than 72.56% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 28.50% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 14.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Scienture Holdings was 38.90% per year. The lowest was -40.70% per year. And the median was 11.90% per year.
Scienture Holdings (NAS:SCNX) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Scienture Holdings 3-Year EPS without NRI Growth Rate Related Terms
SCNX vs PMHS, HEWA, BLMH: 3-Year EPS without NRI Growth Rate Comparison
For the Pharmaceutical Retailers subindustry, Scienture Holdings's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scienture Holdings 3-Year EPS without NRI Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Scienture Holdings's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Scienture Holdings's 3-Year EPS without NRI Growth Rate falls into.
Scienture Holdings 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 28.50% mean?
Scienture Holdings (SCNX) has a 3-Year EPS without NRI Growth Rate of 28.50% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Scienture Holdings and its competitors. This is 139% above median its historical median of 11.90. According to the industry distribution chart, Scienture Holdings ranks #138 out of 503 companies in the Healthcare Providers & Services industry, placing it in the top 27.4%.
Is Scienture Holdings' 3-Year EPS without NRI Growth Rate too high?
Scienture Holdings' current 3-Year EPS without NRI Growth Rate of 28.50% is 139% above median its 10-year median of 11.90. The Healthcare Providers & Services industry median 3-Year EPS without NRI Growth Rate is 11.00. Scienture Holdings' value of 28.50% is 159.1% above this industry median. Based on the distribution chart, Scienture Holdings ranks #138 out of 503 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Scienture Holdings has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Scienture Holdings' 3-Year EPS without NRI Growth Rate compare to PMHS and HEWA?
According to the Healthcare Providers & Services industry distribution chart, Scienture Holdings ranks #138 out of 503 companies for 3-Year EPS without NRI Growth Rate. This puts Scienture Holdings in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 11.00. Scienture Holdings' value of 28.50% is 159.1% above this benchmark. While the company's 10-year median is 11.90 vs. the industry median of 11.00, Scienture Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EPS without NRI Growth Rate among Healthcare Providers & Services companies is 11.00, based on 503 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scienture Holdings's current 3-Year EPS without NRI Growth Rate of 28.50% is 159.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Scienture Holdings and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EPS without NRI Growth Rate is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scienture Holdings's current 3-Year EPS without NRI Growth Rate is 28.50%, which is 139% above median its own 10-year median of 11.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scienture Holdings stock overvalued right now?
Based on GuruFocus' analysis, Scienture Holdings (SCNX) is currently considered Possible Value Trap. The stock's GF Value™ is $0.51, compared to a current price of $0.33 — trading 35% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 28.50%, which is 139% above median its 10-year median of 11.90 and 159.1% above the Healthcare Providers & Services industry median of 11.00. Scienture Holdings' overall GF Score™ is 43/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Scienture Holdings (SCNX), the current 3-Year EPS without NRI Growth Rate is 28.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scienture Holdings (SCNX) Overvalued in 2026?
Based on GuruFocus' analysis, Scienture Holdings stock appears to be undervalued.
The current stock price of $0.33 is trading 35% below its estimated GF Value™ of $0.51.
GuruFocus considers Scienture Holdings to be Possible Value Trap.
Key valuation signals for SCNX:
3-Year EPS without NRI Growth Rate: 28.50% (139% above median its 10-year median of 11.90)
GF Value™: $0.51 vs. price of $0.33 (35% below fair value)
Industry Position: 159.1% above the Healthcare Providers & Services median (#138 of 503)
No single metric tells the full story. See the SCNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
43GF Score
Get the complete analysis for SCNX
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCNX has been successfully added to your 
